ArcanaBio, announced today a milestone collaboration agreement with the North Texas Genome Center (NTGC). The agreement provides ArcanaBio with access to the NTGC's state-of-the-art laboratory infrastructure, offering a significant boost to the company's research and development capabilities as well as early-stage diagnostics pilot tests with clients in the Dallas region.
Located at the University of Texas at Arlington, the North Texas Genome Center is one of the six major sequencing laboratories in the United States. It boasts an advanced suite of next-generation sequencing technologies and bioinformatics tools and systems. The center's mission is to provide genomic insights to accelerate advances in healthcare, agriculture, environmental sciences, and fundamental biological understanding.
"This agreement presents an extraordinary opportunity for ArcanaBio to both enhance our genomic research capabilities but at the same have access to a high throughput diagnostics platform in one of the most modern and state-of-the-art research facilities in the United States," said Kristján Már, CEO of ArcanaBio. "Access to NTGC's cutting-edge infrastructure allows us to build upon our strengths and will allow us to test our services next year"